Nolink Bio Recognized as World Economic Forum 2025 Technology Pioneer for Leading Nitric Oxide Therapeutics Innovation

On June 23, local time, the World Economic Forum announced the selection of the 100 Technology Pioneers for 2025.Noliving Biotech, a global leading medical enterprise with a nitric oxide technology platform, has been successfully selected.

The 100 selected startups, hailing from 28 countries, are driving innovation across nations and industries. This year marks the 25th anniversary of the Technology Pioneers community, and this year’s cohort represents the strongest lineup in history. It not only covers a broader geographic range and reflects diversity beyond Silicon Valley, but also signals the rise of more ambitious frontier technologies.

“Engaging in technological innovation has never been more exciting. But only by working together can we go further; you need a community to advance your mission,” said Verena Kuhn, Head of the World Economic Forum’s Community of Innovators. “As we celebrate the 25th anniversary of the Technology Pioneers program, this global community will continue to help startups connect with networks and ecosystems, supporting them in scaling up.”

Since its establishment in 2000, the Technology Pioneers community has been at the forefront of early-stage innovation, selecting more than 1,200 Technology Pioneers, many of which are already reshaping industries worldwide. Among past honorees, names such as Google, PayPal, Dropbox, and SoundCloud have become household words, fully demonstrating the pivotal role of the Technology Pioneers community in sparking ideas and amplifying impact.

This year, a total of 11 Chinese companies made the list, with Noliving Biotech being the only healthcare enterprise among them. As this year’s Technology Pioneer, Noliving Biotech prioritizes technological innovation and is committed to making innovative diagnostic and therapeutic technologies convenient, accessible, and affordable for all.

Noliving Biotech’s innovations in the field of nitric oxide are bringing safer and more accessible treatment options to patients. As a “life-saving gas” for critical conditions such as pulmonary hypertension and hypoxic respiratory failure, nitric oxide (NO) has traditionally relied on industrial steel cylinders for delivery, posing challenges including inconvenient transportation, limited supply, and high operational risks. Noliving Biotech has independently developed a portable NO inhalation therapy device that leverages globally leading “electrochemical catalytic on-demand generation technology” to produce high-purity gas instantly for immediate use. This innovation completely eliminates dependence on steel cylinders and logistics infrastructure. The compact and lightweight device seamlessly integrates pre-hospital emergency care, patient transport, and in-hospital treatment, thereby securing the golden window for life-saving intervention.

Noliving Biotech is also committed to contributing to the well-being of patients worldwide. The company has expanded its footprint into Latin America, the Middle East, and Southeast Asia, forging partnerships with healthcare institutions in multiple countries. By facilitating the adoption of innovative diagnostic and therapeutic solutions in more developing nations, Noliving Biotech aims to enhance their critical care capabilities and ultimately create more medical miracles. In doing so, it offers Chinese solutions to address the global imbalance in healthcare resource distribution.

As the founder and CEO of Noliving Biotech, Mao Wen was also invited to participate in the World Economic Forum’s Annual Meeting of the New Champions (also known as “Summer Davos”), where she moderated the panel discussion on “Smart Healthcare: Reducing Costs, Improving Health.” She led in-depth dialogues with other panelists and the audience, exploring how digitalization and AI technologies can benefit more patients in healthcare settings.

Attendees shared insights on the scalable breakthroughs AI has achieved in consumer healthcare, significantly enhancing service accessibility and safety. Mao Wen then keenly advanced the discussion by asking, “Can the AI revolution’s experience in consumer healthcare be successfully replicated in serious medical care, or even in critical care areas where lives are at stake?” She guided participants to jointly explore this pivotal question—how AI and digitalization can truly empower high-risk medical decision-making, which is precisely the direction Noliving Biotech continues to strive toward.

In her concluding remarks, Mao Wen issued a compelling call to action: She urged the entrepreneurs and policymakers in attendance to more actively embrace digitalization and AI technologies, and to courageously tackle the challenges inherent in critical healthcare scenarios. Artificial intelligence offers new perspectives, scenarios, solutions, and approaches, potentially reshaping many hidden clinical needs and significantly improving the efficiency of standardizing clinical cognition. For instance, with AI assistance, primary care institutions and low-income, resource-constrained regions may gain better access to high-end services and more efficient diagnostic and treatment paradigms. By accelerating the inclusive adoption of technology, we can ensure that innovative achievements benefit physicians and patients worldwide more rapidly and extensively.

As China’s first gas-based theranostic platform enterprise, Noliving Biotech focuses on technologies for the on-demand generation and precise regulation of nitric oxide (NO), with a product portfolio spanning NO therapy, monitoring, and exhaled breath analysis. Guided by its mission to “create life miracles with nitric oxide,” Noliving Biotech is committed to making innovative diagnostic and therapeutic technologies more convenient, accessible, and affordable.

Launched in 2000, the Technology Pioneers community celebrated its 25th anniversary in 2025. This leading platform brings together early-stage companies from around the world that are actively shaping the future through breakthrough technologies and innovation. Selected companies demonstrate the potential to make a significant impact on business and society, and they are invited to participate in the World Economic Forum’s global platforms to engage and collaborate with leaders from the public and private sectors.

The “Technology Pioneers” community is part of the Forum’s Centre for the Fourth Industrial Revolution Innovators Community. The Innovators Community brings together leading global startups at various stages of development, including early-stage Technology Pioneers, growth-stage global innovators, and unicorn companies valued at over $1 billion.